EUVIMEDEUVIMED entdecken
Crossref

Urine proteomics uncovers biomarker candidates for early identifying rituximab beneficiaries in paediatric steroid‐resistant immune thrombocytopenia

Yuncui Yu iD, Xingjuan Xie iD, Zhenping Chen iD, Jing Wei, Juntao Ouyang, Zheyan Lin, Jingyao Ma iD, Peng Guo, Runhui Wu iD, Lulu Jia, Jingang Gui iD

British Journal of Haematology · 2025-10 · 207 (4) · 1323-1333

DOI: 10.1111/bjh.70072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 08.08.2025. Verfasst von Yuncui Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Bei…. Hauptthemen laut MEDLINE: Rituximab, Proteomics, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Clinical Research Fund of Wu Jieping Medical Foundation, Children Medication Program of Beijing Children's Hospital, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rituximab (RTX) is an effective treatment for children with steroid‐resistant immune thrombocytopenia (ITP), but reliable biomarkers to predict its response early are lacking. We analysed urine samples from 37 steroid‐resistant ITP patients—17 RTX responders (RTX‐R) and 20 RTX non‐responders (RTX‐NR)—along with 40 healthy controls using a discovery‐validation proteomics workflow. In the discovery cohort, we identified 78 differential proteins (DPs) before treatment and 67 DPs after treatment using the data‐independent acquisition (DIA) approach. The RTX‐R group was associated with humoral immunity and complement activation before treatment, while the RTX‐NR group showed stronger connections to cellular immunity and glycolysis. The Mfuzz analysis indicated that RTX worked by reducing the B‐cell receptor pathway and lipid metabolism while enhancing platelet activation. We validated two proteins (KLK6 and FUBP1) as candidate biomarkers for predicting RTX response through parallel reaction monitoring (PRM) technology, achieving an area under the curve (AUC) of 0.98, with a sensitivity of 1.00 and specificity of 0.85. A monitoring model with HK1, FUBP1, LAIR2, CSTA and RPL12 differentiated RTX‐R from RTX‐NR after treatment, yielding an AUC of 1.00, sensitivity of 0.92 and specificity of 0.95. Overall, these findings enhance our understanding of RTX mechanisms and support personalized therapy development for ITP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabProteomicsPurpura, Thrombocytopenic, IdiopathicHumansChildBiomarkersMaleFemaleChild, PreschoolAdolescentDrug ResistanceSteroids

Stichwörter der Autor:innen

biomarkerimmune thrombocytopeniapaediatricrituximaburine proteomics

Substanzen

RituximabBiomarkersSteroids

Autor:innen und Institutionen

  • Clinical Research Center, Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Hematology Department, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Be…
  • Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Department of Clinical Laboratory Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Laboratory of Tumor Immunology, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

ORCID-Profile: Yuncui Yu, Xingjuan Xie, Zhenping Chen, Jingyao Ma, Runhui Wu, Jingang Gui

Förderung

  • Clinical Research Fund of Wu Jieping Medical Foundation
  • Children Medication Program of Beijing Children's Hospital
  • National Natural Science Foundation of China
  • Funding for Reform and Development of Beijing Municipal Health Commission

Zitieren

APA

Yu, Y., Xie, X., Chen, Z., Wei, J., Ouyang, J., Lin, Z., Ma, J., Guo, P., Wu, R., Jia, L., & Gui, J. (2025). Urine proteomics uncovers biomarker candidates for early identifying rituximab beneficiaries in paediatric steroid‐resistant immune thrombocytopenia. British Journal of Haematology, 207(4), 1323-1333. https://doi.org/10.1111/bjh.70072

Vancouver

Yu Y, Xie X, Chen Z, Wei J, Ouyang J, Lin Z, et al. Urine proteomics uncovers biomarker candidates for early identifying rituximab beneficiaries in paediatric steroid‐resistant immune thrombocytopenia. British Journal of Haematology. 2025;207(4):1323-1333. doi:10.1111/bjh.70072

BibTeX
@article{Yu2025,
  author = {Yu, Yuncui and Xie, Xingjuan and Chen, Zhenping and Wei, Jing and Ouyang, Juntao and Lin, Zheyan and Ma, Jingyao and Guo, Peng and Wu, Runhui and Jia, Lulu and Gui, Jingang},
  title = {Urine proteomics uncovers biomarker candidates for early identifying rituximab beneficiaries in paediatric steroid‐resistant immune thrombocytopenia},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {207},
  number = {4},
  pages = {1323--1333},
  doi = {10.1111/bjh.70072}
}
Kostenlos starten →